These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21921457)

  • 1. [Acute management and research of stroke in Taiwan: an update].
    Chung CP; Hu HH
    Rinsho Shinkeigaku; 2010 Nov; 50(11):828-9. PubMed ID: 21921457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study.
    Chao AC; Hsu HY; Chung CP; Liu CH; Chen CH; Teng MM; Peng GS; Sheng WY; Hu HH;
    Stroke; 2010 May; 41(5):885-90. PubMed ID: 20224056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of leukoaraiosis on CT for tissue plasminogen activator decision making: evaluation of the NINDS rt-PA Stroke Study.
    Demchuk AM; Khan F; Hill MD; Barber PA; Silver B; Patel S; Levine SR;
    Cerebrovasc Dis; 2008; 26(2):120-5. PubMed ID: 18560214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prospects of thrombolytic therapy for acute ischemic stroke].
    Nakashima T; Minematsu K
    Brain Nerve; 2009 Sep; 61(9):1003-12. PubMed ID: 19803399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus statement on the use of intravenous recombinant tissue plasminogen activator to treat acute ischemic stroke by the Chinese Stroke Therapy Expert Panel.
    Xu AD; Wang YJ; Wang DZ;
    CNS Neurosci Ther; 2013 Aug; 19(8):543-8. PubMed ID: 23710819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan.
    Fang CW; Tsai YT; Chou PC; Chen HM; Lu CM; Tsao CR; Chen CL; Sun MC; Shih YS; Hsieh CY; Chen LA; Chen PL; Yeh JT; Li YH
    J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):815-820. PubMed ID: 30573284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computed Tomography Angiography in Acute Stroke Patients Receiving Recombinant Tissue Plasminogen Activator: Outcome and Safety Evaluations in an Asian Population.
    Lin CM; Wu HC; Wu YM; Liu CH; Chang KH; Chang TY; Huang KL; Chang YJ; Lee TH; Tsay PK; Cheng CK; Chang CH
    Cerebrovasc Dis; 2020; 49(1):62-69. PubMed ID: 32023610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed Dose IV rt-PA and Clinical Outcome in Ischemic Stroke Patients With Body Weight >100 kg: Pooled Data From 3 Randomized Clinical Trials.
    Majidi S; Leon Guerrero CR; Burger KM; Sigounas D; Olan WJ; Qureshi AI
    J Stroke Cerebrovasc Dis; 2018 Oct; 27(10):2843-2848. PubMed ID: 30076113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke.
    Adeoye O; Knight WA; Khoury J; Schmit PA; Sucharew H; Broderick JP; Pancioli AM;
    J Stroke Cerebrovasc Dis; 2014; 23(5):e313-5. PubMed ID: 24534128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator.
    Betts KA; Hurley D; Song J; Sajeev G; Guo J; Du EX; Paschoalin M; Wu EQ
    J Stroke Cerebrovasc Dis; 2017 Sep; 26(9):1996-2003. PubMed ID: 28689999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.
    Pancioli AM; Broderick J; Brott T; Tomsick T; Khoury J; Bean J; del Zoppo G; Kleindorfer D; Woo D; Khatri P; Castaldo J; Frey J; Gebel J; Kasner S; Kidwell C; Kwiatkowski T; Libman R; Mackenzie R; Scott P; Starkman S; Thurman RJ;
    Stroke; 2008 Dec; 39(12):3268-76. PubMed ID: 18772447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT; Wong YS; Wu CS; Su YH
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours after stroke onset.
    Lorenzano S; Toni D;
    Int J Stroke; 2012 Apr; 7(3):250-7. PubMed ID: 22292526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose rt-PA may not decrease the incidence of symptomatic intracranial haemorrhage in patients with high risk of symptomatic intracranial haemorrhage.
    Liu M; Pan Y; Zhou L; Wang Y
    Neurol Res; 2019 May; 41(5):473-479. PubMed ID: 30822264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time of day, outcome, and response to thrombolytic therapy: the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trial experience.
    Rhoney DH; Coplin WM; Lin Y; Frankel M; Lyden PD; Levine SR
    J Stroke Cerebrovasc Dis; 2010 Jan; 19(1):40-8. PubMed ID: 20123226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous thrombolysis with recombinant tissue plasminogen activator for ischemic stroke patients over 80 years old: the Fukuoka Stroke Registry.
    Matsuo R; Kamouchi M; Fukuda H; Hata J; Wakisaka Y; Kuroda J; Ago T; Kitazono T;
    PLoS One; 2014; 9(10):e110444. PubMed ID: 25329379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous Alteplase for Acute Ischemic Stroke in Taiwan: Can We Expand the National Health Insurance's Reimbursement Criteria?
    Hsieh CY
    Acta Neurol Taiwan; 2017 Mar; 26(1):1-2. PubMed ID: 28752507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low- versus Standard-Dose Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: An Updated Meta-Analysis.
    Liu H; Zheng H; Cao Y; Pan Y; Wang D; Zhang R; You S; Zhang X; Li S; Tong X; Liu CF; Wang Y
    J Stroke Cerebrovasc Dis; 2018 Apr; 27(4):988-997. PubMed ID: 29224744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Risk of Hemorrhagic Transformation After Thrombolysis for Acute Ischemic Stroke in Chinese Versus North Americans: A Comparative Study.
    Xu X; Wang D; Wang F; Norton C; Liu X; Selim M
    J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):2381-2387. PubMed ID: 29778315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.